FDA Removes Advair, Symbicort Boxed Warnings For Death Risks

Federal regulators are removing a “black box” warning that was previously placed on the asthma inhalers Advair, Dulera and Symbicort, after a number of recent studies found that the medications do not increase the risk of death.

Since 2010, certain a boxed warning on the asthma inhalers indicated that users may be at risk of sudden death. The label warning was the strongest the FDA can place on a prescription medication, but it will now be removed.

The inhalers all belong to a class of medications that were a combination of long-acting beta agonists (LABAs) and inhaled corticosteroids (ICS), which the FDA indicates no longer appear to carry the same serious risks the agency originally thought.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

In a drug safety communication issued on December 20, the FDA indicates that four large clinical safety trials provide further information, and indicate that the drugs do not increase the risk of serious asthma-related side effects when compared to treatment with inhaled corticosteroids alone.

The studies were commissioned by the FDA in 2011, to get a better understanding of the health risks of LABA/ICS combination asthma treatments. The four studies involved 41,297 patients who were treated for six months. According to the findings of all of the trials, one of which specifically involved children, the inhalers did not significantly increase the risk of serious asthma problems. The agency also indicates that the trials showed that the drugs decreased asthma attacks when compared to inhaled corticosteroids alone.

The list of approved LABA/ICS asthma inhalers includes Advair Diskus, Advair HFA, Airduo Respiclick, Breo Ellipta, Dulera and Symbicort.

The FDA also noted that using long-acting beta agonists alone for the treatment of lung inflammation is still associated with an increased risk of asthma-related death, and a black box warning about those risks will remain in place for all single-ingredient LABA medications.

Asthma is a chronic disease which affects 20 million Americans, including 6.5 million children, causing symptoms like difficulty breathing, spasms and wheezing.

Unlike rescue inhalers, which contain the beta-agonist albuterol and have a limited duration, these long-acting beta agonists are designed to be taken daily to prevent asthma attacks.


  • JuliannaDecember 27, 2023 at 8:29 pm

    I was given Advair in 2012 by my allergist. I had originally been on Flovent and my asthma was fine. He wanted me to try something else. I took it for a few days and couldnt breath. I ended up in the ER with hyper inflated lungs. I stopped the advair and in a month or so the lungs went down. I cannot believe they are taking the black box warning off this stuff its POISON.

  • MarcellaMarch 25, 2020 at 9:39 pm

    Since taking this inhaler. Have lesions I. My lungs and am short. Of breath has disabled me. I cannot function. Any longer

  • DurwinFebruary 18, 2020 at 8:49 pm


  • RobertDecember 25, 2017 at 8:10 pm

    I was born with asthma in 1964.I have taken Advair discus for 20 years. I take many asthma meds still. Adair Pro Air now for 20 to 30 years and others not around today. I am 54 .What recourse and suites am I available for. Still sick with asthms.

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL
Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL (Posted 2 days ago)

The U.S. District Judge presiding over all Suboxone lawsuits has created a mentorship program to use the litigation to provide some attorneys an opportunity to gain experience in handling complex federal multidistrict litigations.

Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M
Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M (Posted 4 days ago)

Gilead says it will pay $40 million to resolve HIV drug lawsuits over Truvada, Atripla, Viread, Stribild and Complera pending in the federal court system, involving claims that the the company sat on safer formulations of the drugs for years to increase profits.